JMIR Publications

ABSTRACT

Background:

Coronavirus disease 2019 (COVID-19) has spread over the world and resulted in extensive and devastating damage. This test, called glycated albumin (GA), can track glycemic management over a period of two to three weeks. Patients with hemoglobinopathy, renal insufficiency, and pregnancy can benefit from GA. Additionally, GA more accurately represents peripheral vascular calcification, nephropathy, retinopathy, arterial stiffness, and Alzheimer's disease than HbA1c.

Objective:

to assess the relationship between the death and morbidity of severe and critical diabetic COVID-19 patients and the glycated albumin biomarker at the time of admission to the intensive care unit. Glycated albumin levels throughout an ICU stay are compared to each patient's SOFA score and APACHE II score at admission.

Methods:

This controlled cross-sectional study (Pilot study) included 60 patients, aged above 18 years old of either sex, admitted for isolation in the Intensive care unit of Ain Shams teaching hospitals and Obour specialized hospital who were PCR positive for COVID-19 during the period of six months from first of April 2022 till first of October 2022.

Results:

There was a highly significant relation between glycated albumin and SOFA score among all studied cases. Groups with high GA are directly proportionated with high SOFA score.

Conclusions:

While SOFA score and APACHE II may be regarded as excellent sensitive indicators for diabetic patient mortality during ICU stay for severe and critical COVID-19, GA may be regarded as a good sensitive predictor for severity. Furthermore, it is a significant indicator for problems related to diabetes during an ICU stay. Conversely, GA does not accurately predict morbidity with respect to cardiac, respiratory, or nephrogenic problems.